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ABSTRACT: Since loss of function mutations of PINK1 lead to
early onset Parkinson’s disease, there has been growing interest
in the discovery of small molecules that amplify the kinase
activity of PINK1. We herein report the design, synthesis, serum
stability, and hydrolysis of four kinetin riboside ProTides. These
ProTides, along with kinetin riboside, activated PINK1 in cells
independent of mitochondrial depolarization. This highlights the
potential of modiﬁed nucleosides and their phosphate prodrugs
as treatments for neurodegenerative diseases.
Parkinson’s disease (PD) is the second most commonneurodegenerative disease in the world.1 It aﬀects around
130 000 people in the U.K. and over 1 million people in the
U.S.1 Considering that current PD therapies and medical
interventions are limited only to addressing the symptoms of
this disease2 coupled with a general rise in lifespan, the rate of
PD incidence in the future is likely to increase signiﬁcantly.
This highlights the need for new and speciﬁc PD treatments. As
part of our eﬀorts into discovering novel PD therapeutics, we
focused on PINK1 (PTEN-induced kinase 1), a protein kinase
mutated in some patients with early onset PD.3
PINK1 is a mitochondrial serine/threonine protein kinase
that possesses a unique N-terminal mitochondrial targeting
sequence, a transmembrane domain, and three insertional loops
within its catalytic kinase domain.4 Following inner mitochon-
drial membrane depolarization, it becomes stabilized on the
outer mitochondrial membrane (OMM) where it phosphor-
ylates the E3 ubiquitin ligase Parkin at serine 65 (Ser65) on its
N-terminal ubiquitin-like domain. Such phosphorylation
activates Parkin, which is also mutated in early onset PD,5
leading to the ubiquitylation of a series of its substrates on the
OMM that act as a signal for the degradation of mitochondria
by autophagy (mitophagy).6
In PD, the majority of PINK1 mutations are located within
its kinase domain and consequently aﬀect its catalytic activity.7,8
This conﬁrms that the kinase activity of PINK1 is critical to the
prevention of neurodegeneration. This notion has been veriﬁed
in Drosophila models of PINK1 in which kinase-inactive
versions of PINK1 failed to rescue neurodegeneration
compared to the wild-type gene.9 Hence, the activation of
PINK1 emerged as a useful strategy to induce and maintain
neuroprotective eﬀects, an approach that would be useful in
treating PD.
To date, reported eﬀorts into the discovery of small
molecules that activate PINK1 led to the identiﬁcation of N6-
furfuryladenine, termed kinetin (1, Figure 1),10 which is
undergoing clinical trials for the treatment of familial
dysautonomia and the prevention from skin photodamage.11
In cells, pronounced activation of PINK1 by kinetin was only
observed following co-incubation with the mitochondria-
depolarizing agent CCCP (carbonyl cyanide m-chlorophenyl-
hydrazine),5 which in itself activates PINK1 in cells.12 Studies
into the mechanism by which PINK1 is activated by kinetin
revealed that kinetin was converted intracellularly in four
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consecutive metabolic steps to the active metabolite kinetin
riboside (KR) triphosphate 4, which acts as a PINK1 ATP-
neosubstrate (Figure 1).10
Given that the cellular activation of synthetic nucleobases
and their nucleoside derivatives may be of limited eﬃciency as
compared to natural nucleobases and nucleosides, we explored
the direct use of the KR monophosphate intermediate (3) as an
activator of PINK1. Using this metabolite, 3, instead of kinetin
to activate PINK1 in cells would bypass two important
activation steps, glycosylation and the ﬁrst phosphorylation
step, that kinetin must undergo consecutively. This suggests
that KR monophosphate would be a more potent activator of
PINK1 than kinetin. As nucleoside monophosphates often have
poor in vivo stability and ineﬃcient cellular uptake, we
employed the ProTide prodrug technology13 to deliver KR
monophosphate into cells. This prodrug technology has
inspired the discovery of two FDA-approved (antiviral)
nucleotide monophosphate and monophosphonate drugs with
many more undergoing clinical trials.14
The synthesis of KR ProTides started by making kinetin
riboside in a single step from 6-chloropurine riboside (10) as
reported (Figure 2).15 This involved reﬂuxing 6-chloropurine
riboside with furfurylamine in ethanol in the presence of
triethylamine. The pure product was subsequently coupled16
with the appropriate phosphorochloridate (6−9) in the
presence of tBuMgCl or NMI as a base to aﬀord the desired
KR ProTides (11−14).
In the design of these ProTides, the amino acid of the
ProTides was ﬁxed as L-alanine, since this historically17 has
given the optimum biological activity and is processed well by
enzymes during the metabolism of the ProTides in vivo. A
small selection of ester motifs was used in this study [methyl
(Me), isopropyl (iPr), tert-butyl (tBu), and benzyl (Bn)] to
probe the inﬂuence of these moieties on the ProTides’
biological activity.
Since these ProTides are prodrugs aimed at delivering KR
monophosphate, we initially explored the hydrolysis of the
phosphate masking groups to release the naked KR mono-
phosphate. The intracellular metabolism18 of ProTides is
known to be triggered by esterase enzymes, such as cathepsin
A,19 which cleave oﬀ the ester motif (Figure 3). The generated
carboxylate group (15) undergoes a nucleophilic attack on the
phosphate group resulting in the loss of the phenyl group and
the formation of an unstable ﬁve-membered heterocyclic ring
(16). A water molecule subsequently attacks the phosphate
group to open this ring and generate metabolite 17. Finally, a
phosphoramidase-type enzyme, e.g., Hint-1,20−22 hydrolyzes
the P−N bond of metabolite 17 leading to the release of the
KR monophosphate.
To probe the hydrolysis of KR ProTides to release KR
monophosphate, we followed the hydrolysis of the KR ProTide
14 by 31P NMR in the presence of recombinant cathepsin A
(Figure 4A).16 We chose KR ProTide 14 as it has an L-alanine
isopropyl moiety akin to the two ProTides approved for use in
the clinics, e.g., sofosbuvir and tenofovir alafenamide, which
both bear the same L-alanine isopropyl ester moiety.17 Before
the addition of the enzyme, ProTide 14 (in acetone-d6) showed
two peaks (δP 3.58 and 3.88) corresponding to its two
diastereoisomers. After ∼15 min incubation with cathepsin A in
Trizma buﬀer, two peaks at δP 3.7 and 4.1 appeared, which
correspond to the parent ProTide diastereoisomers under the
acetone-d6/Trizma buﬀer. After ∼2 h, a new peak at δP 6.81
started appearing. This corresponds to metabolite 17 in
agreement with previous reports.16 Following 12 h, almost all
of ProTide 14 was converted to metabolite 17 and after 48 h
incubation a new peak, δP −0.11, appeared, a typical 31P NMR
shift of nucleoside monophosphates. Indeed, negative ion
electrospray ionization mass spec analysis of the sample showed
that this new peak had a mass of 426.1 g/mol, which matches
the mass of KR monophosphate 3 (MW = 427.31 g/mol)
(Supporting Information Figure S1). Although in this sample,
there was no phosphoramidase-type enzyme, e.g., Hint-1, that
cleaves the P−N bond of intermediate 17 to generate the
monophosphate species, it appears that the P−N bond of
metabolite 17 was unstable under the assay condition after >48
Figure 1. Chemical structure of kinetin (1) and its metabolism in cells
to generate the active substrate kinetin riboside triphosphate (4).
Figure 2. Synthesis of kinetin riboside and its ProTides. Reagents and
conditions: (i) POCl3, TEA, Et2O, −78 °C; (ii) L-alanine ester
hydrochloride, TEA, DCM, −78 °C; (iii) furfurylamine, TEA, EtOH,
N2, 77 °C, (iv)
tBuMgCl or NMI, DCM, N2, rt.
Figure 3. Postulated mechanism of in vivo metabolism of ProTides to
release nucleoside analogue monophosphates.
Journal of Medicinal Chemistry Brief Article
DOI: 10.1021/acs.jmedchem.6b01897
J. Med. Chem. 2017, 60, 3518−3524
3519
h of incubation. Together, the data indicated that incubation of
a KR ProTide with cathepsin A triggered its hydrolysis to the
major metabolite 17 with a trace of KR monophosphate.
To verify whether the kinetin riboside amidate 17 would be a
good substrate for the carboxypeptidase Hint-1, which cleaves
the P−N bonds of phosphoramidates,20−22 we performed in
silico docking of metabolite 17 into the cocrystal structure of
Hint-1 with AMP (Figure 4B). Analysis of the diﬀerent
predicted poses indicated that the KR nucleobase was stabilized
by hydrophobic interactions with two phenylalanine residues
(F19 and F41) and isoleucine (I44). Critically, the phosphate
moiety was placed where the phosphate group of AMP was
located while the phosphoramidate motif was positioned in a
pocket that included the key amino acid residues required for
the Hint-1 catalytic activity (serine 107, histidines 112 and
114). Such position suggests that metabolite 17 is likely to be
processed by Hint-1 to release KR monophosphate, in
agreement with previous conclusions.16
Subsequently, we examined the stability of KR ProTides in
human and mouse serum in situ. For this, we incubated KR
ProTide 14 in human (Figure 4C) or mouse serum
(Supporting Information Figure S2) at 37 °C and followed
the sample by 31P NMR. At t = 0, two close 31P NMR signals δP
4.0 and 4.5 ppm corresponding to the two diastereoisomers of
KR ProTide 14 were present. The time-course 31P NMR
revealed that no new peaks appeared that may correspond to
new metabolites. Indeed, following ∼11 h incubation in human
and mouse serum there were no changes in the 31P NMR
signals that correspond to the KR ProTide indicating its
stability in these environments. Additionally, we studied the
stability of KR ProTides in acid environment. For this, we
incubated ProTide 14 in acidic buﬀer, pH 1, and monitored it
by 31P NMR over 12 h. The data showed that the ProTide was
completely stable in this acidic environment, pH 1, since the
phospho peaks corresponding to ProTide 14 persisted
throughout the 12 h period studied (Supporting Information
Figure S3).
Once the hydrolysis and stability of KR ProTides were
established, we then investigated their ability to activate PINK1
in cells. Brieﬂy, HEK293 Flp-In TRex HEK293 cells stably
expressing wild-type PINK1 were co-transfected with untagged
wild type Parkin. Upon activation, PINK1 directly phosphor-
ylates Parkin at Ser65,23 and this phosphorylation site was used
as a readout for the activity of PINK1 in cells. Initially, the cells
were treated with 50 μM kinetin, KR, or KR ProTides (11−14)
for 24 h (Figure 5).
Interestingly three out of the four KR ProTides showed
activation of PINK1, as judged by Parkin Ser65 phosphor-
ylation in the absence of CCCP treatment. KR ProTide 13
exhibited the most signiﬁcant activation followed by ProTides
14 and 11. Notably, KR also showed signiﬁcant activation of
PINK1 while treatment with kinetin did not lead to noticeable
PINK1 activation in the absence of CCCP.
The activation of PINK1 by KR ProTides indicates that the
ProTides were metabolized to release KR monophosphate,
which was then further phosphorylated to the active
triphosphate counterpart to act as a PINK1 ATP-neosubstrate.
This possibility is supported by the lack of PINK1 activation
with KR ProTide 12, which has the tBu ester motif that is
known to be poorly metabolized in vivo by esterases as
compared to ProTides with Me, iPr, and Bn esters.13 In fact, in
vitro cathepsin A hydrolysis of KR ProTide 12 was very slow
after a 12 h incubation with the esterase enzyme cathepsin A as
∼50% of the parent ProTide remained intact (Supporting
Information Figure S4) in contrast to ProTide 14, which was
rapidly hydrolyzed (Figure 5). The fact that KR showed
comparable PINK1 activation to KR ProTides suggests that the
ﬁrst phosphorylation step by which KR is converted into its
monophosphate species, and which is bypassed by the
ProTides, is not the rate limiting step but is its activation.
This is seen with other therapeutic nucleosides such as
Figure 4. Metabolism and serum stability of KR ProTides. (A) 31P
NMR of cathepsin A mediated in vitro degradation of KR ProTide 14.
(B) Docking of metabolite 17 into the crystal structure of Hint-1 to
predict the cleavage of the P−N bond. (C) Stability of KR ProTide 14
in human serum over 12 h as monitored by 31P NMR.
Figure 5. Activation of PINK1 by KR ProTides in cells. Flp-In TRex
HEK293 cells stably expressing PINK1 were transfected with wild-type
Parkin. Cells were transfected with 50 μM KR ProTides 11−14,
kinetin, or kinetin riboside for 24 h. Cells were then lysed and probed
with anti-phospho Ser65 Parkin (pS65 Parkin), total parkin, PINK1,
and vinculin antibodies. *NS: nonspeciﬁc band.
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lamivudine and zidovudine for which the ﬁrst phosphorylation
step is not the rate-limiting in their activation but the second or
the third phosphorylation steps.24
Since the activation of PINK1 by KR and its ProTides was
determined after a 24 h incubation (Figure 5), we next
determined the time-dependent activation of PINK1 in cells by
the most potent KR ProTide activator of PINK1, 13. Under
similar conditions, we treated cells with ProTide 13 for 3, 6, 12,
24, and 48 h (Figure 6). The data show that KR ProTide 13
activated PINK1 in a time-dependent manner with the most
prominent activation observed after a 24 h treatment. The
activation, however, was not as signiﬁcant as achieved with
CCCP, and no phosphorylation of Parkin was detected in cells
expressing the Parkin S65A mutant as expected.
In conclusion, we herein described the ﬁrst application of the
powerful ProTide phosphate prodrug technology to elaborate
nucleoside-based molecules that activate PINK1 in cells. Of the
four KR ProTides synthesized and studied in this work, three
KR ProTides showed activation of the kinase activity of PINK1
with KR ProTide 13 exhibiting the highest potency. Uniquely,
this activation was independent of CCCP, a mitochondrial
depolarizing agent, which has been used previously10 in
identifying kinetin as an activator of PINK1. In view of the
ability of these KR ProTides to activate PINK1, it may be
promising to optimize these further as potential neuro-
protective agents for PD. Such endeavor is supported by the
favorable human and mouse serum stability proﬁles of these
ProTides in addition to their encouraging stability in acidic
environments. Notably, our approach of using the ProTide
technology in developing protein kinase activators has the
potential to be expanded to the discovery of ATP-neosubstrates
for other protein kinases beyond PINK1 and neurodegenera-
tion.
■ EXPERIMENTAL SECTION
General Information. Dichloromethane, diethyl ether, methanol,
and toluene were dried in-house using a Pure Solv-MD solvent
puriﬁcation system. All the other solvents were used as received from
commercial suppliers. All of the other reagents used in the synthesis
were purchased from Sigma-Aldrich except L-alanine isopropyl ester.
All reactions were carried out under an argon atmosphere. Reactions
were monitored with analytical TLC on silica gel 60-F254 precoated
aluminum plates and visualized under UV (254 nm) and/or with 31P
NMR spectra. Column chromatography was performed on silica gel
(35−70 μM). NMR data were recorded on a Bruker AV300, AVIII300,
AV400, AVIII400, or DRX500 spectrometer in the deuterated solvents
indicated, and the spectra were calibrated on residual solvent peaks.
Chemical shifts (δ) are quoted in ppm, and J values are quoted in Hz.
In reporting spectral data, the following abbreviations were used: s
(singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets),
and m (multiplet). HPLC was carried out on a DIONEX summit P580
quaternary low pressure gradient pump with a built-in vacuum
degasser using a Summit UVD 170s UV/vis multichannel detector.
Solvents were used as HPLC grade. Chromeleon software was used to
visualize and process the obtained chromatograms. Analytical
separations used a ﬂow rate of 1 mL/min, semipreparative used a
ﬂow rate of 3 mL/min, and preparative used a ﬂow rate of 20 mL/min.
All tested compounds had a purity of ≥95% as shown by HPLC or
elemental analysis (see Supporting Information).
Kinetin Riboside (2).15 Furfurylamine (0.54 mL, 6.2 mmol) and
Et3N were added dropwise to a suspension of 6-chloropurine riboside
10 (600 mg, 2.1 mmol) in EtOH (30 mL). This was reﬂuxed for 18 h
at 60 °C. The resulting yellow solution was evaporated under reduced
pressure to yield the crude mixture as a cream paste. This was washed
with Et2O (3 × 25 mL) and ﬁltered to give the product as a white
crystalline solid (679 mg, 93%). 1H NMR (400 MHz, MeOD) δ 8.26
(2H, s, H-2/H-8), 7.43 (1H, dd, J = 1.9, 0.9 Hz, CH2ArO-H), 6.34
(1H, dd, J = 3.2, 1.8 Hz, CH2ArO-H), 6.31 (1H, dd, J = 3.2, 0.9 Hz,
CH2ArO-H), 5.95 (1H, d, J = 6.4 Hz, 1′-H), 4.80 (2H, s, NH2CH2),
4.74 (1H, dd, J = 6.4, 5.1 Hz, 2′-H), 4.31 (1H, dd, J = 5.1, 2.5 Hz,
3′H), 4.16 (1H, q, J = 2.5 Hz, 4′-H), 3.81 (2H, ddd, J = 57.3, 12.6, 2.6
Hz, 5′-H2); 13C NMR (100 MHz, MeOD) 152.0 (C-8/C-2), 151.6
(CH2ArO-C), 149.6, 147.8 (ArN-C), 142.0 (CH2ArO-CH), 140.3 (C-
8/C-2), 119.9 (ArN-C), 110.0 (CH2ArO-CH), 106.9 (CH2ArO-CH),
89.9 (1′-C), 86.8 (4′-C), 74.0 (2′-C), 71.3 (3′-C), 62.1 (5′-C), 36.7
(NHCH2). MS-ESI (m/z): C15H17N5O5 [M + Na]
+ 370.1.
Phenyl (Methoxy-L-alaninyl)phosphorochloridate (6).16 L-
Alanine methyl ester hydrochloride (400 mg, 2.9 mmol) was dissolved
in anhydrous CH2Cl2 (20 mL) under an inert atmosphere. Following
this, phenyl phosphorodichloridate (0.53 mL, 2.9 mmol) was added
dropwise over 15 min. Et3N (0.77 mL, 5.8 mmol) was then added at
−78 °C, and the mixture was stirred for 30 min. The solution was then
allowed to warm to room temperature over 2 h. Solvent was then
removed under reduced pressure and the remaining white precipitate
suspended in anhydrous Et2O (50 mL). This was ﬁltered and the
ﬁltrate evaporated under reduced pressure, yielding the crude product
as a light brown oil. Puriﬁcation via ﬂash column chromatography gave
the pure product as a colorless oil (729 mg, 91%) (eluent 7:3 EtOAC/
hexane). 31P NMR (120 MHz, CDCl3) δ 7.94, 7.62;
1H NMR (400
MHz, CDCl3) δ 7.45−7.33 (2H, m, Ar-H), 7.31−7.21 (3H, m, Ar-H),
4.62−4.52 (1H, m, N-H), 4.26−4.14 (1H, m, CHCH3), 3.79, 3.77
(2H, 2 s, OCH3), 1.51 (3H, dd, J = 7.1, 4.1 Hz, CHCH3);
13C NMR
(100 MHz, CDCl3) δ 173.4 (COCH3), 150.1 (Ar-COP), 130.3, 126.4,
121.0 (Ar-CH), 53.3 (OCH3), 51.1 (CHCH3), 20.9 (CHCH3).
Phenyl (tert-Butyloxy-L-alaninyl)phosphorochloridate (7).16
Prepared as described for 6 using L-alanine tert-butyl ester hydro-
chloride (400 mg, 2.20 mmol), phenyl phosphorodichloridate (0.30
mL, 2.20 mmol), and Et3N (0.60 mL, 4.4 mmol). Product 7 was
obtained as a pale yellow oil, which was used in sequential steps
without further puriﬁcation (803 mg, 114%). 31P NMR (120 MHz,
CDCl3) δ 8.26, 7.84;
1H NMR (400 MHz, CDCl3) δ 7.44−7.32 (2H,
m, Ar-H), 7.30−7.20 (3H, m, Ar-H), 4.28 (1H, br s, NH), 4.12−3.98
(1H, m, CHCH3), 1.56−1.34 (3H, m, CHCH3, 9H, m, OCtBu); 13C
NMR (100 MHz, CDCl3) δ 171.9 (COCO
tBu), 149.9 (Ph-COP),
130.0, 126.1, 120.1 (Ph-CH), 82.9 (OCtBu), 51.0 (CHCH3), 28.1
(OCtBu), 20.8 (CHCH3).
Phenyl (Benzyloxy-L-alaninyl)phosphorochloridate (8).16
Prepared as described for 6 using L-alanine benzyl ester hydrochloride
(500 mg, 2.32 mmol), phenyl phosphorodichloridate (0.35 mL, 2.32
mmol), and Et3N (0.63 mL, 4.64 mmol). Product 8 was obtained a
pale yellow oil (505 mg, 95%). 31P NMR (120 MHz, CDCl3) δ 7.85,
7.49; 1H NMR (400 MHz, CDCl3) δ 7.40−7.32 (m, 5H, Ph-H), 7.28−
7.21 (m, 5H, Ph-H), 5.21 (2H, d, J = 6.1 Hz, OCH2Ph), 4.31−4.15
(2H, 2 m, CHCH3), 1.52 (3H, dd, J = 6.6, 2.4 Hz CHCH3);
13C NMR
(100 MHz, CDCl3) δ 172.6 (COOCH2Ph), 149.7 (Ph-C), 135.0 (Ph-
Figure 6. Time-dependent activation of PINK1 by KR ProTide 13 in
cells. Flp-In TRex HEK293 cells stably expressing PINK1 were
transfected with wild-type or S65A Parkin. Experiment was performed
as in Figure 5.
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C), 130.0, 128.7, 128.6, 128.4, 126.0, 120.6 (Ph-CH), 67.6 (OCH2Ph),
50.8 (CHCH3), 20.6 (CHCH3).
Phenyl (Isopropoxy-L-alaninyl)phosphorochloridate (9).16
Prepared as described for 6 using L-alanine isopropyl ester hydro-
chloride (700 mg, 4.18 mmol), phenyl phosphorodichloridate (0.62
mL, 4.18 mmol), and Et3N (1.13 mL, 8.36 mmol). Product 9 was
obtained as a yellow oil (1185 mg, 93%). 31P NMR (120 MHz,
CDCl3) δ 8.10, 7.80;
1H NMR (400 MHz, CDCl3) δ 7.46−7.32 (2H,
m, Ar-H), 7.30−7.19 (3H, m, Ar-H), 5.16−5.00 (1H, m, OCHiPr),
4.50−4.30 (1H, m, N-H), 4.22−4.03 (1H, m, CHCH3), 1.52−1.47
(3H, m, CHCH3), 1.32−1.22 (6H, m, OCHiPr); 13C NMR (100
MHz, CDCl3) δ 172.2 (COCH3), 149.9 (Ar-COP), 130.0, 126.1, 120.7
(Ar-CH), 69.8 (OCHiPr), 50.8 (CHCH3), 21.8 (2C, OCH
iPr), 20.6
(CHCH3).
Phenyl (Methoxy-L-alaninyl) Kinetin Riboside Phosphorami-
date (11). KR 2 (200 mg, 0.60 mmol) was suspended in anhydrous
THF (15 mL) under an inert atmosphere. To this, tBuMgCl (0.09 mL,
0.68 mmol) was then added dropwise over 15 min. The resulting
solution was stirred for 10 min, and following this, 6 (241 mg, 0.86
mmol) in anhydrous THF (1.5 mL) was then added dropwise over 10
min. The mixture was left to stir for 18 h. MeOH (2 mL) was then
added to quench the reaction before solvent was removed under
reduced pressure to leave the crude product as a pale yellow oil. This
was puriﬁed via ﬂash column chromatography and then preparative
TLC to yield the ﬁnal product as a white solid (34 mg, 10%) (eluent
3:97 to 5:95 MeOH/CH2Cl2).
31P NMR (120 MHz, MeOD) δ 3.84,
3.69; 1H NMR (400 MHz, MeOD) δ 8.27 (1H, s, ArN-CH), 8.23,
8.20 (1H, 2 s, ArN-CH), 7.43 (1H, m, CH2ArO-H), 7.30 (2H, t, J =
7.9 Hz, Ph-H), 7.22−7.12 (3H, m, Ph-H), 6.34 (1H, dd, J = 3.4, 1.8
Hz, CH2ArO-H), 6.32 (1H, d, J = 2.8 Hz, CH2ArO-H), 6.04 (1H, t, J
= 5.0 Hz, 1′-H), 4.80 (2H, br s, NHCH2), 4.70−4.60 (1H, m, 2′H),
4.46−4.30 (3H, m, 3′H/5′H2), 4.29−4.23 (1H, m, 4′-H), 3.95−3.77
(2H, 2 m, CHCH3), 3.61 (3H, s, OCH3), 1.30−1.27 (3H, m,
CHCH3);
13C NMR (100 MHz, MeOD) δ 175.5 (COOCH3), 154.0
(ArN-CH), 153.4 (ArO-C), 152.1 (Ph-C), 150.3 (ArN-C), 143.4
(ArO-CH), 140.7 (ArN-CH), 130.7, 126.2, 121.9 (Ph-CH), 120.9
(ArN-C), 111.4, 108.2 (ArO-CH), 90.0 (1′-C), 84.4 (4′-C), 75.4 (2′-
C), 71.6 (3′-C), 67.3 (5′-C), 52.7 (OCH3), 51.4 (CHCH3), 38.4
(NHCH2), 20.3 (CHCH3). HRMS-ESI (m/z): calcd for
C25H29N6O9NaP [M + Na]
+ 611.1631, found 611.1633. Found: C
51.2, H 5.3, N 14.2. Calcd for C25H29N6O9P: C 51.0, H 4.97, N 14.3%.
Phenyl (tert-Butyloxy-L-alaninyl) Kinetin Riboside Phosphor-
amidate (12). Prepared as described for compound 11 using KR 2
(200 mg, 0.60 mmol), NMI (0.22 mL, 3.00 mmol), and 7 (552 mg,
1.80 mmol). The crude product was puriﬁed via ﬂash column
chromatography to yield the ﬁnal product as a white solid (52 mg,
14%) (eluent 3:97 to 5:95 MeOH/CH2Cl2).
31P NMR (120 MHz,
MeOD) δ 3.91, 3.84; 1H NMR (400 MHz, MeOD) δ 8.22 (1H, s,
ArN-CH), 8.22, 8.19 (1H, 2 s, ArN-CH), 7.43 (1H, dd, J = 1.9, 0.9 Hz,
CH2ArO-H), 7.35−7.26 (2H, m, Ph-H), 7.21−7.10 (3H, m, Ph-H),
6.34 (1H, dd, J = 3.2, 1.9 Hz, CH2ArO-H), 6.32−6.30 (1H, m,
CH2ArO-H), 6.05−6.02 (1H, m, 1′-H), 4.79 (2H, s, NHCH2), 4.65
(1H, t, J = 5.2 Hz, 2′H), 4.48−4.30 (3H, m, 3′-H/5′H2), 4.29−4.24
(1H, m, 4′-H), 3.82−3.75 (1H, m, CHCH3), 1.39 (9H, s, tBu-H), 1.23
(3H, dd, J = 7.1, 1.2 Hz, CHCH3);
13C NMR (100 MHz, MeOD) δ
172.9 (CO), 154.3 (ArN-C), 152.6 (ArNC-H), 151.8 (ArO-C), 150.7
(PhCOP), 148.6 (ArN-C), 142.0 (ArOC-H), 139.3 (ArNC-H), 129.4,
124.7, 120.0 (PhC-H), 119.2 (ArN-C), 110.0, 106.8 (ArOC-H), 88.6
(1′-C), 83.0 (4′-C), 81.2 (OCtBu), 74.0 (2′-C), 70.2 (3′-C), 65.7 (5′-
C), 50.8 (CHCH3), 37.1 (NHCH2), 26.8 (3C, OC
tBu), 19.1
(CHCH3). HRMS-ESI (m/z): calcd for C28H35N6O9NaP [M +
Na]+ 653.2101, found 653.2104. Found: C 53.4, H 5.6, N 13.5. Calcd
for C28H35N6O9P: C 53.3, H 5.6, N 13.3%.
Phenyl (Benzyloxy-L-alaninyl) Kinetin Riboside Phosphor-
amidate (13). Prepared as described for compound 11 using 2 (250
mg, 0.72 mmol), NMI (0.29 mL, 3.6 mmol), and 8 (765 mg, 2.16
mmol). The crude product was puriﬁed via ﬂash column
chromatography to yield the ﬁnal product as a white solid (60 mg,
13%) (eluent 3:97 to 5:95 MeOH/CH2Cl2).
31P NMR (120 MHz,
MeOD) δ 3.89, 3.64; 1H NMR (400 MHz, MeOD) δ 8.26 (1H, s,
ArN-CH), 8.20, 8.17 (1H, 2 s, ArN-CH), 7.41 (1H, d, J = 1.8,
CH2ArO-H), 7.32−7.24 (7H, m, Ph-H), 7.21−7.06 (3H, m, Ph-H),
6.32 (1H, dd, J = 3.3, 1.9 Hz, CH2ArO-H), 6.29 (1H, d, J = 3.2 Hz,
CH2ArO-H), 6.03 (1H, t, J = 4.9 Hz, 1′-H), 5.18−4.98 (2H, 2 m,
CH2Ph), 4.77 (2H, br s, NHCH2), 4.67−4.57 (1H, m, 2′-H), 4.43−
4.33 (3H, m, 3′-H/4′-H/5′-H), 4.33−4.20 (1H, m, 5′-H), 4.02−3.85
(1H, m, CHCH3), 1.25 (3H, dd, J = 19.4, 7.0 Hz, CHCH3);
13C NMR
(100 MHz, MeOD) δ 174.8 (COOCH2Ph), 155.8 (ArN-C), 153.9
(ArN-CH), 152.0 (Ph-C), 150.2 (ArN-C), 143.3 (ArO-CH), 140.6
(ArN-CH), 139.0 (Ph-CH), 137.1 (Ph-C), 130.7, 129.2, 128.8, 126.2,
121.9, 121.3 (Ph-CH), 121.0 (ArN-C), 111.4, 108.2 (ArO-CH), 89.9
(1′-CH), 84.3 (4′-C), 75.4 (2′-CH), 71.4 (3′-CH), 67.7 (CH2Ph),
67.1 (5′-C), 51.5 (CHCH3), 38.2 (NHCH2), 20.4 (CHCH3). HRMS-
ESI (m/z): calcd for C31H33N6O9NaP [M + Na]
+ 687.1944, found
687.1942. Found: C 55.95, H 5.2, N 12.6. Calcd for C31H33N6O9P: C
56.0, H 5.0, N 12.65%.
Phenyl (Isopropoxy-L-alaninyl) Kinetin Riboside Phosphor-
amidate (14). Prepared as described for compound 11 using 2 (250
mg, 0.72 mmol), NMI (0.29 mL, 3.60 mmol), and 9 (660 mg, 2.16
mmol). The crude product was puriﬁed via ﬂash column
chromatography to yield the ﬁnal product as a white solid (185 mg,
42%) (eluent 3:97 to 5:95 MeOH/CH2Cl2).
31P NMR (120 MHz,
CDCl3) δ 3.02, 2.86;
1H NMR (400 MHz, CDCl3) δ 8.27 (1H, s,
ArN-CH), 7.98, 7.94 (1H, 2 s, ArN-CH), 7.30 (1H, dd, J = 2.5, 1.4 Hz,
CH2ArO-H), 7.15 (2H, t, J = 7.7 Hz, Ph-H), 7.07 (2H, d, J = 7.7 Hz,
Ph-H), 7.00 (1H, m, Ph-H), 6.74 (1H, br s, NHCH2ArO), 6.25 (2H, t,
J = 1.7 Hz, CH2ArO-H), 5.98 (1H, t, J = 4.4 Hz, 1′-H), 5.38 (1H, br s,
O-H), 4.96−4.85 (1H, m, OCHiPr), 4.78 (2H, br s, NHCH2ArO),
4.57−4.25 (6H, m, NHCHCH3, 2′-H, 3′-H, 4-H, 5′-H2), 3.94−3.81
(1H, m, NHCHCH3), 1.24 (3H, t, J = 7.2 Hz, NHCHCH3), 1.19−
1.05 (6H, m, OCHiPr); 13C NMR (100 MHz, CDCl3) δ 172.9 (CO),
154.0 (ArNC), 152.6 (ArNC-H), 151.4 (ArO-C), 150.2 (Ph-C), 148.5
(ArNC), 142.0 (ArO-CH), 138.6 (ArNC-H), 129.4 (Ph-CH), 124.7
(Ph-CH), 119.8 (Ph-CH), 119.6 (ArNC), 110.6 (ArO-CH), 107.3
(ArO-CH), 88.9 (1′-C), 83.1 (4′-C), 74.5 (2′-C), 70.4 (3′-C) 68.9
(OCHiPr), 65.8 (5′-C), 50.0 (NHCHCH3), 37.2 (NHCH2ArO), 21.4
(OCHiPr), 20.5 (NHCHCH3). HRMS-ESI (m/z): calcd for
C27H34N6O9P [M + H]
+ 617.2125, found 617.2144. HPLC
CH3CN/H2O 0:100 to 100:0 in 30 min, λ = 254 nm, tR = 16.51,
16.69 min.
Cathepsin A Assay. Procedure was adapted from Mehellou et al.16
ProTide 14 (5.0 mg) was dissolved in acetone-d6 (0.15 mL), followed
by addition of Trizma buﬀer (0.30 mL, pH 7.4). After recording a
control 31P NMR spectrum containing ProTide in acetone-d6 and
buﬀer, defrosted cathepsin A (0.1 mg dissolved in 0.15 mL of Trizma
buﬀer) was added to the mixture. A 31P NMR was then run
immediately after the addition and then at even time intervals over 11
h. The sample was then analyzed by 31P NMR after 24 and 48 h. All
31P NMR spectra recorded at 22 °C (±1).
Serum Stability. Procedure was adapted from Slusarczyk et al.25
ProTide 14 (5.0 mg) was dissolved in DMSO-d6 (0.10 mL) and D2O
(0.15 mL). All 31P NMR spectra were recorded at 37 °C. Two control
spectra were recorded, one containing ProTide 14 (5.0 mg) in
DMSO-d6 (0.10 mL) and D2O (0.15 mL) and the other containing
defrosted human serum (0.3 mL), DMSO-d6 (0.10 mL), and D2O
(0.15 mL). Following this, a previously defrosted serum (human or
mouse) (0.30 mL) was added to the NMR tube and a spectrum
immediately run. Spectra were recorded at 30 min after the addition
and then at even time intervals over 11 h.
Acid Stability. Procedure was adapted from Slusarczyk et al.25 To
ProTide 12 (5 mg) in methanol-d4 (0.25 mL) was added acidic buﬀer,
pH 1 (prepared from equal parts of 0.2 M HCl and 0.2 M KCl). The
sample was then subjected to 31P NMR experiments at 37 °C, and the
spectra were recorded every 20 min over 12 h.
Docking Studies. PC Windows 7 with Intel Core i7-4790/3.6GHz
microprocessor, 16 GB RAM, and 64 bit operating system was used to
execute the computational studies. Docking was performed applying
the molecular modeling modules, namely, Omega2, FRED, and VIDA
provided by OpenEye Scientiﬁc Software (http://www.eyesopen.
com). The three-dimensional crystal structure of the cocrystallized
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AMP with the human HINT1 was retrieved from the Protein Data
Bank (PDB code 1KPF),26 and the active site was subsequently
identiﬁed on the basis of the bound ligand. Multiple conformers for
metabolite 17 were generated by Omega2 using the default settings.27
FRED (fast rigid exhaustive docking) implements a rigid docking
approach to ﬁt these conformers into the predeﬁned binding site and
rank the poses by scoring functions.28,29 The VIDA module was then
used to visualize and inspect the docked poses within the receptor’s
active site and to identify the main interacting residues.
Cell Studies. Flp-In T-Rex HEK293 cells stably expressing PINK1-
FLAG wild-type were generated previously.23 Cells were maintained in
DMEM (Dulbeco’s modiﬁed Eagle medium) supplemented with 10%
(v/v) fetal bovin serum, 2 mM L-glutamine, 100 U/mL penicillin, and
0.1 mg/mL streptomycin, plus 15 μg/mL blasticidin and 100 μg/mL
hygromycin at 37 °C under a 5% CO2 atmosphere. On day 0, cells
were seeded in DMEM. One day 1, cells were transiently transfected
with wild type or S65A Parkin using polyethylenimine (Polysciences)
according to the manufacturer’s instruction. One day 2, PINK1-FLAG
overexpression was induced by adding 0.1 μg/mL doxycycline in
DMEM for 24 h before treating cells with compounds or
mitochondrial uncoupler, CCCP, as indicated in the ﬁgure legends.
All compounds were dissolved in DMSO.
Sample Preparation and Immunoblotting. This was carried
out as we reported previously.23 Lysis Buf fer Used: 50 mM Tris-HCl
(pH 7.5), 1 mM EDTA, 1 mM EGTA, 1% (w/v) Triton, 1 mM
sodium orthovanadate, 10 mM sodium glycerophosphate, 50 mM
sodium ﬂuoride, 10 mM sodium pyrophosphate, 0.25 M sucrose, 0.1%
(v/v) 2-mercaptoethanol, 1 mM benzamidine, 0.1 mM PMSF, and
protease inhibitor cocktail (Roche). Antibodies Used: Mouse
monoclonal anti-PINK1 antibody (human PINK1 residues 125−
539) was raised by Dundee Cell Products, anti-vinculin and anti-
GAPDH antibodies were obtained from Cell Signaling Technology,
anti-Parkin phospho-serine 65 rabbit monoclonal antibody was raised
by Epitomics in collaboration with the Michael J. Fox Foundation for
Research, and anti-Parkin mouse monoclonal antibody was obtained
from Santa Cruz.
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